Please assess the completion status of the following clinical trial:

Trial Title: A Single Dose Study of MK-8266 (MK-8266-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* For Panel A and B Participant is a healthy male between 18 to 45 years of age. For Panel C Participant is a male with essential hypertension between 18 to 55 years of age~* A non-smoker~Exclusion Criteria:~* Has a history of stroke, chronic seizure or major neurological disorder~* Has a disability that can interfere with rising from a sitting position to the standing position~* Has a personal of family history of bleeding or clotting disorders~* Has a history of cancer~* Is unable to refrain from or anticipates the use of any prescription or nonprescription drug during the study~* Consumes excessive amounts of caffeine or alcohol~* Has had major surgery, donated blood or participated in another investigational study in the past 4 weeks

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Panel A, Healthy Male Participants, Sequence 1 (Type: EXPERIMENTAL): MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
- Panel A, Healthy Male Participants, Sequence 2 (Type: EXPERIMENTAL): MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
- Panel A, Healthy Male Participants, Sequence 3 (Type: EXPERIMENTAL): MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.
- Panel A, Healthy Male Participants, Sequence 4 (Type: EXPERIMENTAL): MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
- Panel B, Healthy Male Participants, Sequence 1 (Type: EXPERIMENTAL): MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.
- Panel B, Healthy Male Participants, Sequence 2 (Type: EXPERIMENTAL): MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
- Panel B, Healthy Male Participants, Sequence 3 (Type: EXPERIMENTAL): MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
- Panel B, Healthy Male Participants, Sequence 4 (Type: EXPERIMENTAL): MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.
- Panel C, Mild/Moderate Hypertension, Sequence 1 (Type: EXPERIMENTAL): Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
- Panel C, Mild/Moderate Hypertension, Sequence 2 (Type: EXPERIMENTAL): Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
- Panel C, Mild/Moderate Hypertension, Sequence 3 (Type: EXPERIMENTAL): Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
- Panel C, Mild/Moderate Hypertension, Sequence 4 (Type: EXPERIMENTAL): Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
- Panel C, Mild/Moderate Hypertension, Sequence 5 (Type: EXPERIMENTAL): Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
- Panel C, Mild/Moderate Hypertension, Sequence 6 (Type: PLACEBO_COMPARATOR): Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na

Based on this trial design, predict the completion outcome and termination type (if applicable).